Skip to content

Oral Cleft Prevention Trial in Brazil

Oral Cleft Prevention Trial in Brazil

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00098319
Enrollment
2200
Registered
2004-12-07
Start date
2004-01-31
Completion date
2007-04-30
Last updated
2013-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cleft Lip, Cleft Palate

Keywords

Cleft palate, Cleft lip, Folic acid, Global Network, Maternal and child health, International, Women's health, Brazil, Brasil, Latin America, ECLAMC, Congenital defects, Pregnancy

Brief summary

Cleft lip and palate are a significant component of morbid human birth defects in the developing world. By supplementing a high-risk group of women with folic acid (4.0 mg versus 0.4 mg) from preconception and continuing throughout the first 3 months of pregnancy in the state of Sao Paulo, Brazil, this study aims to reduce the recurrence of cleft lip and palate.

Detailed description

Craniofacial anomalies and cleft lip with or without cleft palate (CL/P) are a model for the impact of birth defects on fetal and neonatal health directly and maternal health indirectly. Craniofacial anomalies comprise a significant component of morbid human birth defects. The primary hypothesis is that folic acid supplementation of 4mg/day at preconception and during the first three months of pregnancy will decrease the recurrence of nonsyndromic cleft lip with or without clef palate (NSCL/P) in a high-risk group of women when compared to women taking 0.4 mg per day of folic acid. The total sample will include 2,000 women (that either have NSCL/P or that have at least one child with NSCL/P) randomly assigned to the 4 mg versus the 0.4 mg folic acid study groups. The study will also compare the recurrence rates of NSCL/P in the total sample of subjects as well as the two study groups (4mg, 0.4 mg) to that of a historical control group. The primary outcome assessed is the rate of recurrences of NSCL/P in offspring of the trial mothers in each of the two study groups. Secondary outcomes include recurrence of NSCL/P compared to a historical control group; serum and red cell folate levels; severity of NSCL/P in offspring of trial mothers; twinning rate; miscarriage rate; preeclampsia; rates of other birth defects; birth weight; and gestational age. The sample size was based on historic tables of birth rates and the rates of cleft occurrences. The study hypothesizes that a total of 2000 subjects will be enrolled during a 2.5 year period; a dropout rate of 10%; birth rate for group A (women with NSCL/P) of 10% and a rate of 12% for group B (women with at least one child with NSCL/P); risk of cleft for group A is 7% and for group B is 4%; one-sided test with continuity correction.

Interventions

DRUGFolic acid (0.4mg vs. 4.0mg)

Sponsors

Global Network for Women's and Children's Health Research
CollaboratorOTHER
Bill and Melinda Gates Foundation
CollaboratorOTHER
National Institute of Dental and Craniofacial Research (NIDCR)
CollaboratorNIH
Fogarty International Center of the National Institute of Health
CollaboratorNIH
National Center for Complementary and Integrative Health (NCCIH)
CollaboratorNIH
National Cancer Institute (NCI)
CollaboratorNIH
RTI International
CollaboratorOTHER
University of Iowa
CollaboratorOTHER
Hospital de Reabilitação de Anomalias Craniofaciais (HRAC) - Brazil
CollaboratorOTHER
NICHD Global Network for Women's and Children's Health
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE

Eligibility

Sex/Gender
FEMALE
Age
16 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* All women must reside in the state where the clinic is located. * Women with NSCL/P who attend the craniofacial clinics, who are 16 to 45 years of age (after age 45 fecundity decreases substantially)who attend the craniofacial clinic for their care. * Women (ages 16 to 45 years of age) who have at least one natural child of any age with NSCL/P who receives care at the participating craniofacial clinics.

Exclusion criteria

* Cases resulting from consanguineous couples (first, second, and third degree, i.e., first cousins or closer). * Couples where at least one of the two is definitely sterilized. * Women on anti-epileptic drugs. * Women who are pregnant. * Women who are planning to move outside of the state where the clinic is located within the next year. * Women who are planning to move outside of Sao Paulo state within the next year. * Women who have B12 deficiency (B12 level is below 174 pg/ml or 134.328 pmol/L). * Women who have an allergy to folic acid.

Design outcomes

Primary

MeasureTime frame
Recurrence of nonsyndromic cleft lip with or without cleft palate (NSCL/P) in offspring of trial mothers

Secondary

MeasureTime frame
Serum and red cell folate levels
Severity of NSCL/P in offspring of trial mothers
Twinning rate
Miscarriage rate
Recurrence of NSCL/P compared to a historical control group; Overall and high versus low dose
Rates of other birth defects
Birth weight
Gestational age
Preeclampsia

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026